Objective

We aimed to analyze clinical outcomes from patients with severe COVID-19 pneumonia that received either baricitinib plus dexamethasone or dexamethasone monotherapy.

Methodology

We performed a retrospective comparative study. Data from hospitalized patients with severe COVID-19 pneumonia (saturation <93%, bilateral pulmonary infiltrates) that were treated with baricitinib plus dexamethasone or dexamethasone were collected. Our primary objective was to compare overall mortality and secondly to compare progression to mechanical ventilation and over infection rates.

Results

A total of 793 patients were assessed for inclusion criteria, 596 were excluded and 197 were analyzed for primary outcome: 123 in the baricitinib plus dexamethasone group and 74 in the dexamethasone monotherapy group. The mean age was 59.9 years (SD ± 14.5) and 62.1% (123/197) were male. 42.9% (85/197) of the cases required ICU admission and 25.8% (51/197) underwent invasive mechanical ventilation (IMV). Overall thirty-day mortality was 27.9% (55/197); Mortality was significantly lower in the baricitinib plus dexamethasone group compared to the dexamethasone monotherapy group (20.3% vs 40.5%, P = <.05). There was no difference in hospital acquired infections between both groups.

Conclusion

Thirty-day mortality was significantly lower in patients with COVID-19 pneumonia treated with baricitinib plus dexamethasone versus dexamethasone monotherapy. No difference was observed in progression to invasive mechanical ventilation and hospital acquired infections.

中文翻译：

---

巴瑞克替尼联合地塞米松与地塞米松治疗重症 COVID-19 肺炎的回顾性分析

客观的

我们的目的是分析接受巴瑞克替尼加地塞米松或地塞米松单一疗法的重症 COVID-19 肺炎患者的临床结果。

方法

我们进行了一项回顾性比较研究。收集了接受巴瑞克替尼加地塞米松或地塞米松治疗的重症 COVID-19 肺炎住院患者（饱和度 <93%，双肺浸润）的数据。我们的主要目标是比较总体死亡率，其次是比较机械通气的进展和过度感染率。

结果

共有 793 名患者接受了纳入标准评估，596 名患者被排除，197 名患者接受了主要结局分析：巴瑞克替尼加地塞米松组 123 名，地塞米松单药治疗组 74 名。平均年龄为 59.9 岁 (SD ± 14.5)，62.1% (123/197) 为男性。42.9% (85/197) 的病例需要入住 ICU，25.8% (51/197) 的病例接受有创机械通气 (IMV)。总体 30 天死亡率为 27.9% (55/197)；与地塞米松单药治疗组相比，巴瑞克替尼联合地塞米松组的死亡率显着降低（20.3% 对 40.5%，P  = <.05）。两组之间的医院获得性感染没有差异。

结论

与地塞米松单一疗法相比，接受巴瑞克替尼联合地塞米松治疗的 COVID-19 肺炎患者的 30 天死亡率显着降低。在有创机械通气和医院获得性感染的进展方面没有观察到差异。